l General Information |
Product Name | (+/-)-Sulfinpyrazone |
General description | Sulfinpyrazone is one of the most studied platelet COX inhibitors, also a uricosuric agent that competitively inhibits uric acid reabsorption in kidney proximal
tubules. |
Synonym | G-28315, NSC 75925, 4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione |
Purity | ≥97.0%(HPLC) | CAS Number | 57-96-5 |
Formula | C23H20N2O3S | Molecular Weight | 404.48 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | Solid |
Solubility(25°C) | DMSO | ≥45mg/ml |
Ethanol | ≥45mg/ml |
Water | Very slightly soluble |
l Biological Information |
Biochem/Physiol
Actions | Sulfinpyrazone is a phenylbutazone derivative with uricosuric and antithrombotic properties. Sulfinpyrazone competitively inhibits reabsorption of urate at the proximal renal tubule in the kidney. This agent acts on the organic anion transport exchanger, thereby increasing uric acid excretion and decreasing serum uric acid levels resulting in the prevention of urate deposition. Sulfinpyrazone also blocks tubular excretion of various acidic drugs, resulting in increased serum concentration of the drugs. In addition, sulfinpyrazone and its active metabolite inhibit the synthesis of thromboxane A2, by competitively inhibiting the activity of cyclooxygenase, thereby preventing platelet aggregation through restoration of platelet survival time to normal, and decreasing platelet adhesiveness to subendothelial cells. |
l Storage |
Storage temp. | -20°C |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
